{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:17:06Z","timestamp":1794845826820,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Aimmune Therapeutics, a Nestl\u00e9 Health Science company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Peanut allergy and its current management, involving peanut avoidance and use of rescue medication during instances of accidental exposure, are burdensome to patients and their caregivers and can be a source of stress, uncertainty, and restriction. Physicians may also be frustrated with a lack of effective and safe treatments other than avoidance in the current management of peanut allergy. Efficacy, determined using double-blind, placebo-controlled food challenges (DBPCFCs), of oral immunotherapy with peanut (<jats:italic>Arachis hypogaea<\/jats:italic>) allergen powder-dnfp (PTAH; Palforzia<jats:sup>\u00ae<\/jats:sup>) was demonstrated versus placebo in children and adolescents aged 4 to 17\u00a0years in multiple phase 3 trials; continued benefit of PTAH was shown in a follow-on trial. The DBPCFC is a reproducible, rigorous, and clinically meaningful assessment accepted by regulatory authorities to evaluate the level of tolerance as an endpoint for accidental exposures to peanut in real life. It also provides useful clinical and patient-relevant information, including the amount of peanut protein an individual with peanut allergy can consume without experiencing dose-limiting symptoms, severity of symptoms, and organs affected upon ingestion of peanut protein. We explored symptoms of peanut exposure during DBPCFCs from phase 3 and follow-on trials of PTAH to further characterize treatment efficacy from a perspective relevant to patients, caregivers, and clinicians.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Symptom data recorded during screening and\/or exit DBPCFCs from participants aged 4 to 17\u00a0years receiving PTAH or placebo were examined post hoc across three PTAH trials (PALISADE [ARC003], ARC004 [PALISADE follow-on], and ARTEMIS [ARC010]). The maximum peanut protein administered as a single dose during DBPCFCs was 1000\u00a0mg (PALISADE and ARTEMIS) and 2000\u00a0mg (ARC004). Symptoms were classified by system organ class (SOC) and maximum severity. Endpoints were changes in symptom severity and freedom from symptoms (ie, asymptomatic) during DBPCFC. Relative risk (RR) was calculated for symptom severity by SOC and freedom from symptoms between groups; descriptive statistics were used to summarize all other data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The risk of any respiratory (RR 0.42 [0.30\u20130.60], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), gastrointestinal (RR 0.34 [0.26\u20130.44], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), cardiovascular\/neurological (RR 0.17 [0.08\u20130.39], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), or dermatological (RR 0.33 [0.22\u20130.50], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) symptoms was significantly lower in participants treated with PTAH versus placebo upon exposure to peanut at the end of the PALISADE trial (ie, exit DBPCFC). Compared with placebo-treated participants (23.4%), the majority (76.3%) of PTAH-treated participants had no symptoms at the exit DBPCFC when tested at the peanut protein dose not tolerated (ie, reactive dose) during the screening DBPCFC. Significantly higher proportions of PTAH-treated participants were asymptomatic at doses\u2009\u2264\u2009100\u00a0mg in the exit DBPCFC compared with placebo-treated participants (PALISADE: 69.35% vs 12.10%, RR 5.73 [95% confidence interval (CI) 3.55\u20139.26]; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001; ARTEMIS: 67.42% vs 13.95%, RR 4.83 [95% CI 2.28\u201310.25]; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001); findings were similar at peanut protein doses\u2009\u2264\u20091000\u00a0mg (PALISADE: RR 15.56 [95% CI 5.05\u201347.94]; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001; ARTEMIS: RR 34.74 [95% CI 2.19\u2013551.03]; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). In ARC004, as the period of PTAH maintenance became longer, greater proportions of participants were asymptomatic at doses of peanut protein\u2009\u2264\u20091000\u00a0mg in the exit DBPCFC (from 37.63% after\u2009~\u20096\u00a0months of maintenance treatment [exit DBPCFC of PALISADE] to 45.54% after\u2009~\u200913\u00a0months and 58.06% after\u2009~\u200920\u00a0months of overall PTAH maintenance treatment).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PTAH significantly reduced symptom severity due to exposure to peanut, which is clinically relevant. When exposed to peanut, participants with peanut allergy treated with PTAH rarely had moderate or severe respiratory or cardiovascular\/neurological symptoms. Oral immunotherapy with PTAH appears to reduce frequency and severity of allergic reactions in individuals with peanut allergy after accidental exposure to peanut and may enable them and their families to have an improved quality of life.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov, NCT02635776, registered 17 December 2015, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02635776?term=AR101&amp;draw=2&amp;rank=7\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02635776?term=AR101&amp;draw=2&amp;rank=7<\/jats:ext-link>; ClinicalTrials.gov, NCT02993107, registered 08 December 2016, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993107?term=AR101&amp;draw=2&amp;rank=6\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993107?term=AR101&amp;draw=2&amp;rank=6<\/jats:ext-link>; ClinicalTrials.gov, NCT03201003, registered 22 June 2017, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03201003\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03201003<\/jats:ext-link>? term\u2009=\u2009AR101&amp;draw\u2009=\u20092&amp;rank\u2009=\u20099<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-023-00757-8","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:28:34Z","timestamp":1679862514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct02635776","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02993107","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03201003","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Katharina","family":"Blumchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kleinheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vogelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergejus","family":"Butovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Norval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Du Toit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"issue":"3","key":"757_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.18176\/jiaci.0143","volume":"27","author":"RA Wood","year":"2017","unstructured":"Wood RA. Oral immunotherapy for food allergy. J Investig Allergol Clin Immunol. 2017;27(3):151\u20139.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"757_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/all.14666","volume":"76","author":"JA Lieberman","year":"2021","unstructured":"Lieberman JA, Gupta RS, Knibb RC, Haselkorn T, Tilles S, Mack DP, et al. The global burden of illness of peanut allergy: a comprehensive literature review. Allergy. 2021;76(5):1367\u201384.","journal-title":"Allergy"},{"issue":"3","key":"757_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1398-9995.2008.01843.x","volume":"64","author":"RM King","year":"2009","unstructured":"King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. Allergy. 2009;64(3):461\u20138.","journal-title":"Allergy"},{"issue":"4","key":"757_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/MOP.0000000000000509","volume":"29","author":"MS Shaker","year":"2017","unstructured":"Shaker MS, Schwartz J, Ferguson M. An update on the impact of food allergy on anxiety and quality of life. Curr Opin Pediatr. 2017;29(4):497\u2013502.","journal-title":"Curr Opin Pediatr"},{"issue":"3","key":"757_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1081-1206(10)60908-8","volume":"96","author":"ME Bollinger","year":"2006","unstructured":"Bollinger ME, Dahlquist LM, Mudd K, Sonntag C, Dillinger L, McKenna K. The impact of food allergy on the daily activities of children and their families. Ann Allergy Asthma Immunol. 2006;96(3):415\u201321.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"757_CR6","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1111\/all.14363","volume":"75","author":"A DunnGalvin","year":"2020","unstructured":"DunnGalvin A, Blumchen K, Timmermans F, Regent L, Schnadt S, Podesta M, et al. APPEAL-1: a multiple-country European survey assessing the psychosocial impact of peanut allergy. Allergy. 2020;75(11):2899\u2013908.","journal-title":"Allergy"},{"issue":"2","key":"757_CR7","doi-asserted-by":"publisher","first-page":"100512","DOI":"10.1016\/j.waojou.2021.100512","volume":"14","author":"A Nowak-Wegrzyn","year":"2021","unstructured":"Nowak-Wegrzyn A, Hass SL, Donelson SM, Robison D, Cameron A, Etschmaier M, et al. The peanut allergy burden study: impact on the quality of life of patients and caregivers. World Allergy Organ J. 2021;14(2):100512.","journal-title":"World Allergy Organ J"},{"issue":"11","key":"757_CR8","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/cea.13719","volume":"50","author":"A DunnGalvin","year":"2020","unstructured":"DunnGalvin A, Gallop K, Acaster S, Timmermans F, Regent L, Schnadt S, et al. APPEAL-2: a pan-European qualitative study to explore the burden of peanut-allergic children, teenagers and their caregivers. Clin Exp Allergy. 2020;50(11):1238\u201348.","journal-title":"Clin Exp Allergy"},{"key":"757_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.fct.2013.08.030","volume":"62","author":"BC Remington","year":"2013","unstructured":"Remington BC, Baumert JL, Marx DB, Taylor SL. Quantitative risk assessment of foods containing peanut advisory labeling. Food Chem Toxicol. 2013;62:179\u201387.","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"757_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaip.2017.05.006","volume":"6","author":"JL Baumert","year":"2018","unstructured":"Baumert JL, Taylor SL, Koppelman SJ. Quantitative assessment of the safety benefits associated with increasing clinical Peanut thresholds through immunotherapy. J Allergy Clin Immunol Pract. 2018;6(2):457\u201365.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"757_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/cea.12681","volume":"46","author":"A Deschildre","year":"2016","unstructured":"Deschildre A, Elegbede CF, Just J, Bruyere O, Van der Brempt X, Papadopoulos A, et al. Peanut-allergic patients in the MIRABEL survey: characteristics, allergists\u2019 dietary advice and lessons from real life. Clin Exp Allergy. 2016;46(4):610\u201320.","journal-title":"Clin Exp Allergy"},{"key":"757_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/JAA.S159400","volume":"11","author":"BT Prince","year":"2018","unstructured":"Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities. J Asthma Allergy. 2018;11:143\u201351.","journal-title":"J Asthma Allergy"},{"issue":"2","key":"757_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.anai.2020.09.012","volume":"126","author":"B Glassberg","year":"2021","unstructured":"Glassberg B, Nowak-Wegrzyn A, Wang J. Factors contributing to underuse of epinephrine autoinjectors in pediatric patients with food allergy. Ann Allergy Asthma Immunol. 2021;126(2):175\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"757_CR14","doi-asserted-by":"publisher","first-page":"e0241648","DOI":"10.1371\/journal.pone.0241648","volume":"15","author":"V Sharma","year":"2020","unstructured":"Sharma V, Jobrack J, Cerenzia W, Tilles S, Ryan R, Sih-Meynier R, et al. A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy. PLoS ONE. 2020;15(12):e0241648.","journal-title":"PLoS ONE"},{"issue":"2","key":"757_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/iid3.218","volume":"6","author":"J Mantyla","year":"2018","unstructured":"Mantyla J, Thomander T, Hakulinen A, Kukkonen K, Palosuo K, Voutilainen H, et al. The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults. Immun Inflamm Dis. 2018;6(2):307\u201311.","journal-title":"Immun Inflamm Dis"},{"issue":"5","key":"757_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.anai.2020.01.016","volume":"124","author":"ES Chan","year":"2020","unstructured":"Chan ES, Dinakar C, Gonzales-Reyes E, Green TD, Gupta R, Jones D, et al. Unmet needs of children with peanut allergy: Aligning the risks and the evidence. Ann Allergy Asthma Immunol. 2020;124(5):479\u201386.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"757_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.anai.2020.03.028","volume":"125","author":"AC Blackman","year":"2020","unstructured":"Blackman AC, Staggers KA, Kronisch L, Davis CM, Anagnostou A. Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy. Ann Allergy Asthma Immunol. 2020;125(2):196-201.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"757_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/JAA.S141636","volume":"11","author":"T Weinberger","year":"2018","unstructured":"Weinberger T, Sicherer S. Current perspectives on tree nut allergy: a review. J Asthma Allergy. 2018;11:41\u201351.","journal-title":"J Asthma Allergy"},{"issue":"3","key":"757_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/all.15027","volume":"77","author":"M Fernandez-Rivas","year":"2022","unstructured":"Fernandez-Rivas M, Vereda A, Vickery BP, Sharma V, Nilsson C, Muraro A, et al. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy. 2022;77(3):991\u20131003.","journal-title":"Allergy"},{"issue":"5","key":"757_CR20","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jaip.2020.12.029","volume":"9","author":"BP Vickery","year":"2021","unstructured":"Vickery BP, Vereda A, Nilsson C, du Toit G, Shreffler WG, Burks AW, et al. Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study. J Allergy Clin Immunol Pract. 2021;9(5):1879-89.e14.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"21","key":"757_CR21","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","volume":"379","author":"BP Vickery","year":"2018","unstructured":"Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Investigators PGoC, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991\u20132001.","journal-title":"N Engl J Med"},{"issue":"10","key":"757_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S2352-4642(20)30234-0","volume":"4","author":"JO Hourihane","year":"2020","unstructured":"Obh J, Beyer K, Abbas A, Fernandez-Rivas M, Turner PJ, Blumchen K, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Health. 2020;4(10):728\u201339.","journal-title":"Lancet Child Adolesc Health"},{"key":"757_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5414\/ALX02257E","volume":"5","author":"M Worm","year":"2021","unstructured":"Worm M, Reese I, Ballmer-Weber B, Beyer K, Bischoff SC, Bohle B, et al. Update of the S2k guideline on the management of IgE-mediated food allergies. Allergol Select. 2021;5:195\u2013243.","journal-title":"Allergol Select"},{"issue":"5","key":"757_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2011.07.050","volume":"128","author":"T van der Zee","year":"2011","unstructured":"van der Zee T, Dubois A, Kerkhof M, van der Heide S, Vlieg-Boerstra B. The eliciting dose of peanut in double-blind, placebo-controlled food challenges decreases with increasing age and specific IgE level in children and young adults. J Allergy Clin Immunol. 2011;128(5):1031\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"757_CR25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1365-2222.2005.02312.x","volume":"35","author":"JO Hourihane","year":"2005","unstructured":"Hourihane JO, Grimshaw KE, Lewis SA, Briggs RA, Trewin JB, King RM, et al. Does severity of low-dose, double-blind, placebo-controlled food challenges reflect severity of allergic reactions to peanut in the community? Clin Exp Allergy. 2005;35(9):1227\u201333.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"757_CR26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/jim-2020-001422","volume":"68","author":"JH Dunlop","year":"2020","unstructured":"Dunlop JH. Oral immunotherapy for treatment of peanut allergy. J Investig Med. 2020;68(6):1152\u20135.","journal-title":"J Investig Med"},{"issue":"3","key":"757_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1200435","volume":"367","author":"AW Burks","year":"2012","unstructured":"Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"757_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","volume":"114","author":"SG Brown","year":"2004","unstructured":"Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"757_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2021.01.003","volume":"148","author":"TE Dribin","year":"2021","unstructured":"Dribin TE, Schnadower D, Spergel JM, Campbell RL, Shaker M, Neuman MI, et al. Severity grading system for acute allergic reactions: a multidisciplinary Delphi study. J Allergy Clin Immunol. 2021;148(1):173\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"757_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12955-018-0922-y","volume":"16","author":"SK Kim","year":"2018","unstructured":"Kim SK, Jo MW, Kim SH. Health-related quality of life by allergy symptoms in elementary school students. Health Qual Life Outcomes. 2018;16(1):93.","journal-title":"Health Qual Life Outcomes"},{"key":"757_CR31","unstructured":"FDA Briefing Document, Allergenic Products Advisory Committee: Clinical Development of Allergen Immunotherapies for the Treatment of Food Allergy. 2016. https:\/\/fda.report\/media\/97000\/January-21--2016--Allergenic-Products-Advisory-Committee-Meeting-Summary-Minutes.pdf"},{"issue":"2","key":"757_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaip.2018.10.048","volume":"7","author":"K Blumchen","year":"2019","unstructured":"Blumchen K, Trendelenburg V, Ahrens F, Gruebl A, Hamelmann E, Hansen G, et al. Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol Pract. 2019;7(2):479-91.e10.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-023-00757-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:32:51Z","timestamp":1679862771000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-023-00757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1186\/s13223-023-00757-8","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All individual trials received approval from institutional review boards or independent ethics committees and were conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent or assent (as appropriate) was obtained from each participant and\/or their caregiver before trial entry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KBl reports personal fees and\/or grants and\/or nonfinancial support from Aimmune Therapeutics, a Nestl\u00e9 Health Science company, DBV Technologies, HiPP GmbH, Novartis, Allergy Therapeutics, HAL Allergy, ALK, Allergopharma, Nestl\u00e9, and Bausch\u2009+\u2009Lomb, outside the submitted work and other financial and nonfinancial interests from the German Society for Pediatric Allergology & Environmental Medicine (GPA), German Society for Allergology & Clinical Immunology (DGKJ), the German Society for Pediatric Pneumology (GPP), and the German Society of Pneumology (DGP). AK reports study funding, medical writing, honoraria, expert testimony, support for attending meetings\/travel, and participation on a data safety monitoring board or advisory board from Aimmune Therapeutics, a Nestl\u00e9 Health Science company. Other disclosures include AbbVie, Aimmune Therapeutics, a Nestl\u00e9 Health Science company, Almirall, Galderma, Janssen\/JNJ, Leo Pharma, Lilly, Medac, Novartis, and Regeneron\/Sanofi. LK reports study funding and medical writing from Aimmune Therapeutics, a Nestl\u00e9 Health Science company; grants and\/or personal fees from Allergopharma, Viatris, HAL Allergy, ALK-Abello, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT Biotech, Lofarma, Allergy Therapeutics, AstraZeneca, GSK, ImmunoTek, Cassella-med, Novartis, Regeneron Pharmaceuticals, and ROXALL Medizin GmbH; consulting fees from Allergopharma, Viatris, LETI Pharma, Stallergenes, Sanofi, AstraZeneca, and GSK; payment for expert testimony from GSK and Sanofi; other financial or nonfinancial interests from AeDA, DGHNO, Deutsche Akademi fur Allergologie und klinische immunologie, HNO-BV, GPA, and EAACI. KBe reports study funding, medical writing, and processing charges (payment to institution) from Aimmune Therapeutics, a Nestl\u00e9 Health Science company; grants or contracts to institution from ALK and DBV Technologies; consulting fees from reports from Aimmune Therapeutics, a Nestl\u00e9 Health Science company, Bencard, DBV Technologies, and Novartis; payment or honoraria from Aimmune Therapeutics, a Nestl\u00e9 Health Science company, and Allergopharma; participation on a Data Safety Monitoring Board or Advisory Board from Aimmune Therapeutics, a Nestl\u00e9 Health Science company, Bencard, DBV Technologies, and Novartis; leadership or fiduciary role in other board, society, committee unpaid from AGATE-Anaphylaxis Training and Education, German Society for Pediatric Allergology & Environmental Medicin, German Society for Allergology & Clinical Immunology (DGKJ), and German Allergy and Asthma Association. AA reports grants from Aimmune Therapeutics, a Nestl\u00e9 Health Science company, during the conduct of the study; personal fees from DBV Technologies; grants and personal fees from FARE; and personal fees from ALK, outside the submitted work. CV reports study funding and medical writing from Aimmune Therapeutics, a Nestl\u00e9 Health Science company; honoraria for presentation at the German Allergy Congress from DBV Technologies and honoraria for presentation at the Congress of the German Pediatric Society, press conference and launch symposium. SB reports study funding and medical writing from Aimmune Therapeutics, a Nestl\u00e9 Health Science company. RR is an employee of Aimmune Therapeutics, a Nestl\u00e9 Health Science company. DN is an employee of Aimmune Therapeutics, a Nestl\u00e9 Health Science company. SZ is an employee of Aimmune Therapeutics, a Nestl\u00e9 Health Science company. GDT reports study funding and medical writing from Aimmune Therapeutics, a Nestl\u00e9 Health Science company; funding to institution received for active research on Aimmune projects, ARC008, ARC004, and ARC005; active member of Aimmune Therapeutics, a Nestl\u00e9 Health Science company, scientific board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}